Eli Lilly filed six lawsuits targeting peptide suppliers, a med spa, and a compounding pharmacy for allegedly selling unapproved versions of its experimental obesity drug retatrutide.
A Mondaq legal analysis clarifies that July 2026 PCAC votes on six peptides do not authorize compounding. Formal FDA rulemaking is still required.
Large GLP-1 prescribing telehealth platforms are narrowing pharmacy partnerships from dozens to roughly 5–10 503B facilities, PeptideStaff reports.
FDA's adverse event database has recorded more than 1,700 reports tied to compounded semaglutide and tirzepatide, as regulators move to restrict compounding of these drugs.
Eli Lilly is urging payment processors, social platforms, and shippers to cut off retatrutide vendors, filing six new lawsuits and calling for federal prosecutions.
Florida, Texas, California, and four other states reportedly launched a joint enforcement initiative targeting telehealth platforms that prescribe injectable peptides without synchronous clinician evaluation.
A BMJ observational cohort of nearly 53,000 patients found tirzepatide users had a 2.9% major cardiovascular event rate versus 4.4% for sitagliptin, a 32% relative reduction.
The FDA has formally proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closed July 30, 2026, with no final decision timeline announced.
Eli Lilly will keep pursuing a biologics license for retatrutide after a federal court partially vacated the FDA's non-biologic determination, with an appeal now before the 7th Circuit.
A seventh Victorian patient has been hospitalized with acute liver toxicity from counterfeit retatrutide, with the TGA saying clustering suggests a possible contaminated batch issue.
